hydroxyethyl starch
Trials 27 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00633659 | Sep 2007 → Jun 2008 | limb ischemia | Sangart | Completed | No outcome recorded |
| Phase 2 | NCT00199706 | Apr 2002 → Oct 2004 | subarachnoid hemorrhage | Oslo University Hospital | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02502773 | Feb 2016 → Jul 2018 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 3 | NCT00935168 | Dec 2009 → Apr 2012 | — | The George Institute | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07410988 | Jun 2026 → Jun 2029 expected | — | Seoul National University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05726136 | Oct 2023 → Oct 2026 expected | benign neoplasm, colorectal cancer, female reproductive organ cancer, malignant urinary system neoplasm | Joachim Zdolsek | Recruiting | No outcome recorded |
| Phase 4 | NCT03278548 | Sep 2017 → Apr 2022 | acute hypotension | Fresenius Kabi | Completed | No outcome recorded |
| Phase 4 | NCT02009033 | Sep 2011 → Apr 2013 | blood coagulation disease | K. C. Rasmussen | Completed | No outcome recorded |
| Phase 4 | NCT00542516 | Sep 2006 → Nov 2008 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT00308126 | Jun 2005 → Sep 2006 | — | Fresenius Kabi | Completed | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT05712018 | Oct 2023 → Jan 2024 | — | General Hospital of Ningxia Medical University | Completed | No outcome recorded |
| — | NCT05475990 | Jan → Mar 2023 | — | General Hospital of Ningxia Medical University | Completed | No outcome recorded |
| — | NCT04465539 | Jul 2020 → Feb 2024 | — | Tanta University | Completed | No outcome recorded |
| — | NCT03306914 | Oct 2017 → Feb 2019 | — | Cairo University | Completed | No outcome recorded |
| — | NCT02882074 | Jun 2016 → Feb 2020 | — | The Cleveland Clinic | Completed | No outcome recorded |
| — | NCT03107598 | Mar → Sep 2016 | hypotensive disorder | University Hospital, Mahdia | Terminated | No outcome recorded |
| — | NCT02361736 | Mar → Dec 2015 | — | Yuanyuan Zhang | Completed | No outcome recorded |
| — | NCT02208570 | Jul 2014 → Dec 2016 | hypotensive disorder | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT02113358 | Apr 2014 → May 2015 | primary brain neoplasm, supratentorial cancer | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT02034682 | Jan → Aug 2014 | — | University Hospital, Ghent | Completed | No outcome recorded |
| — | NCT02306213 | Jan 2011 → Apr 2013 | — | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| — | NCT01195883 | Nov 2010 → Nov 2016 | — | The Cleveland Clinic | Completed | No outcome recorded |
| — | NCT02337010 | Oct 2010 → Sep 2013 | — | Domonkos Trásy | Completed | No outcome recorded |
| — | NCT01195025 | Aug 2010 → May 2011 | blood coagulation disease | University Hospital, Linkoeping | Completed | No outcome recorded |
| — | NCT01729364 | Apr 2008 → Dec 2014 | impaired renal function disease | Sahlgrenska University Hospital | Completed | No outcome recorded |
| — | NCT00518544 | Jul 2007 → ? | — | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT00255957 | Oct 2005 → Mar 2006 | — | Nizam's Institute of Medical Sciences University, India | Completed | No outcome recorded |
Also used as a comparator or background therapy in 37 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05505708 Comparator | Dec 2022 → Jan 2023 | pulmonary edema | Kasr El Aini Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03465943 Comparator | Mar 2018 → Mar 2019 | hypotensive disorder | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT01530490 Background | Aug 2007 → Aug 2008 | ovarian disorder | Hospital de Cruces | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01087853 Comparator | Mar 2010 → Mar 2011 | disorder of acid-base balance, water intoxication | University of Nottingham | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02622126 Comparator | Jan → Jul 2016 | blood coagulation disease | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT01511120 Comparator | Nov 2011 → Dec 2013 | coronary artery disorder | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00300040 Comparator | May 2006 → Jun 2008 | peripheral vascular disease | Biopure Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00317512 Comparator | Dec 2003 → Apr 2005 | intermediate coronary syndrome, myocardial infarction | Biopure Corporation | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT01028339 Background | Jul 2008 → Jun 2012 | traumatic brain injury | Central Directorate of the Army Health Service | Terminated | No outcome recorded |
| Phase 3 | NCT00444262 Comparator | Apr 2007 → Nov 2010 | bone disorder | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT00420277 Comparator | Feb 2007 → Mar 2008 | hypotensive disorder, ischemic disease | Sangart | Completed | No outcome recorded |
| Phase 3 | NCT00421200 Comparator | Feb 2007 → May 2008 | hypotensive disorder, ischemic disease | Sangart | Completed | No outcome recorded |
| Phase 3 | NCT01120730 Comparator | Apr 1997 → Sep 1998 | kidney failure | University of Zurich | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT02393196 Comparator | Mar 2015 → Jan 2016 | hypotensive disorder | Sifa University | Unknown | No outcome recorded |
| Phase 4 | NCT02064075 Comparator | Feb → Oct 2013 | subarachnoid hemorrhage | University of Debrecen | Completed | No outcome recorded |
| Phase 4 | NCT01486576 Comparator | Jan 2012 → Mar 2013 | osteoarthritis | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 4 | NCT01486563 Comparator | Jan 2012 → Jun 2013 | prostate cancer | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 4 | NCT01486550 Comparator | Dec 2011 → Sep 2014 | kidney cancer | Regional Hospital Holstebro | Terminated | No outcome recorded |
| Phase 4 | NCT01348659 Comparator | May 2011 → May 2012 | — | Kati Järvelä | Completed | No outcome recorded |
| Phase 4 | NCT01741610 Comparator | Oct 2008 → Aug 2011 | — | Cukurova University | Completed | No outcome recorded |
| Phase 4 | NCT01654653 Comparator | Jul 2008 → Mar 2009 | coronary artery disorder | Innogene Kalbiotech Pte. Ltd | Completed | No outcome recorded |
| Phase 4 | NCT00549419 Comparator | Oct 2007 → Jan 2009 | — | Klinikum Ludwigshafen | Completed | No outcome recorded |
| Phase 4 | NCT00517127 Comparator | Sep 2006 → Dec 2016 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01174719 Comparator | Mar 2006 → Feb 2010 | coronary artery disorder, heart valve disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00273728 Comparator | May 2005 → Jun 2010 | infectious disease with sepsis | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT06664320 Comparator | Oct 2024 → Mar 2025 overdue | mitral valve insufficiency, mitral valve stenosis, tricuspid valve insufficiency | Konkuk University Medical Center | Not yet recruiting | No outcome recorded |
| — | NCT03048162 Comparator | Feb → May 2017 | — | Tokat Gaziosmanpasa University | Completed | No outcome recorded |
| — | NCT03249298 Comparator | Jan → Dec 2017 | — | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT02502448 Comparator | Jan → Jun 2016 | mitral valve insufficiency, mitral valve stenosis, tricuspid valve insufficiency | Konkuk University Medical Center | Completed | No outcome recorded |
| — | NCT02599155 Comparator | Nov 2015 → Feb 2016 | acute kidney injury | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT02570724 Comparator | Jun 2013 → Aug 2018 | intracranial hypotension | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| — | NCT01819571 Background | Jan 2012 → Oct 2013 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT01512628 Comparator | Jan 2012 → Dec 2013 | avascular necrosis | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT01452581 Comparator | Oct 2011 → Sep 2012 | osteoarthritis, hip | Rigshospitalet, Denmark | Terminated | No outcome recorded |
| — | NCT00973414 Comparator | Mar → Sep 2009 | — | Nanjing Medical University | Completed | No outcome recorded |
| — | NCT00973791 Comparator | Oct 2008 → May 2009 | — | Nanjing Medical University | Completed | No outcome recorded |
| — | NCT01972828 Background | Jul 2007 → Aug 2013 | infectious disease with sepsis | Hospices Civils de Lyon | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 68 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hydroxyethyl starch | “The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES, voluven) administered by gravity at a wide-open rate over a period of 15-30min before...” NCT03107598 ↗44“Patients undergoing moderate- to high-risk open abdominal surgery were randomly assigned to goal-directed lactated Ringer's solution (n = 58) or a hydroxyethyl starch 6%...” PMID 32825817 ↗ Aug 2020 “This trial aims to compare two intraoperative fluids, namely hydroxyethyl starch (HES) and balanced crystalloids in terms of major adverse kidney events after cardiac surgery.” NCT07410988 ↗ “an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.” NCT01195883 ↗ “In the starch group, 6% hydroxyethyl starch 130/0.4 (Volulyte® ) was used as the primary fluid for volume resuscitation but was limited to 30 ml.kg-1 .” PMID 29150842 ↗ Nov 2017 “250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.” NCT02337010 ↗ “hyperoncotic hydroxyethyl starch (HES) 200/0.5 (10%) administered in combination with crystalloids within the first 24 hours after injury” PMID 20584291 ↗ Jun 2010 “Hydroxyethyl starch (HES) solutions are widely used in surgical patients as a component of goal-directed fluid optimization strategies” PMID 26690683 ↗ Dec 2015 “rapid crystalloid (Lactated Ringer's solution) or colloid (hydroxyethyl starch; HES) cohydration with a second intravenous access line” NCT01741610 ↗ “Infusion of hydroxyethyl starch (HES) impairs coagulation and, in O blood type, apparent coagulopathy can develop after HES infusion.” NCT00518544 ↗ “The two fluids being compared are 0.9% sodium chloride (saline) and 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride,(starch).” NCT00935168 ↗ “6% hydroxyethyl starch (HES) 130/0.4 in a balanced electrolyte solution (Volulyte®)” NCT02034682 ↗ “2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch” NCT01028339 ↗ “hydroxyethyl starch (HES group, Tetraspan®) as CPB priming solution” PMID 29199540 ↗ Dec 2017 “Hydroxy Ethyl Starch administration to stroke patients” NCT00255957 ↗ “Hydroxyethyl starch solution 6ml/kg iv injection” NCT02208570 ↗ “Hydroxyethylstarch up to 50mL/kg/24 hrs” NCT01174719 ↗ |
| Known as | 6% HES | “The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES, voluven) administered by gravity at a wide-open rate over a period of 15-30min before...” NCT03107598 ↗ |
| Known as | 6% Hydroxyethylstarch | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00300040 ↗ |
| Known as | acetated Ringers | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01195025 ↗ |
| Known as | HES | “250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.” NCT02337010 ↗8“hyperoncotic hydroxyethyl starch (HES) 200/0.5 (10%) administered in combination with crystalloids within the first 24 hours after injury” PMID 20584291 ↗ Jun 2010 “rapid crystalloid (Lactated Ringer's solution) or colloid (hydroxyethyl starch; HES) cohydration with a second intravenous access line” NCT01741610 ↗ “Hydroxyethyl starch (HES) solutions are widely used in surgical patients as a component of goal-directed fluid optimization strategies” PMID 26690683 ↗ Dec 2015 “Infusion of hydroxyethyl starch (HES) impairs coagulation and, in O blood type, apparent coagulopathy can develop after HES infusion.” NCT00518544 ↗ “fluid boluses of hydroxyethyl starch (HES) or lactated Ringer's (LR) solution guided by oesophageal Doppler.” PMID 31627889 ↗ Oct 2019 “This study aims to compare hemodynamic effects and fluid balance of HSL with 6% Hydroxy Ethyl Starch (HES).” NCT01654653 ↗ “6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery” NCT02361736 ↗ “Albumin 5%, Hydroxyethylstarch 130/0.4 (HES) and Ringer-Lactate (RL)” NCT01174719 ↗ |
| Known as | HES 130/0.4 | “500 mL hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible...” NCT02393196 ↗4“HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups” NCT01819571 ↗ “6% hydroxyethyl starch (HES) 130/0.4 in a balanced electrolyte solution (Volulyte®)” NCT02034682 ↗ “hydroxyethyl starch (HES) solution (Voluven®; HES 130/0.4)” PMID 21317165 ↗ Feb 2011 “Voluven (HES 130/0.4)” NCT00421200 ↗ |
| Known as | HES 130/0.6 | “hydroxyethyl starch (HES 130/0.6)” NCT06664320 ↗1“hydroxyethyl starch (HES 130/0.6)” NCT02502448 ↗ |
| Known as | hydroxyethyl starch 130/0.4 | “250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.” NCT02337010 ↗ |
| Known as | Tetraspan | “hydroxyethyl starch (HES group, Tetraspan®) as CPB priming solution” PMID 29199540 ↗ Dec 2017 |
| Known as | Venofundin | “Patients were randomized to receive a bolus dose of either a crystalloid (Ringers-acetate 20 ml kg(-1), n=15) or a colloid solution (Venofundin) 10 ml kg(-1), n=15.” PMID 26475802 ↗ Nov 2015 |
| Known as | Volulyte | “In the starch group, 6% hydroxyethyl starch 130/0.4 (Volulyte® ) was used as the primary fluid for volume resuscitation but was limited to 30 ml.kg-1 .” PMID 29150842 ↗ Nov 20172“6% hydroxyethyl starch (HES) 130/0.4 in a balanced electrolyte solution (Volulyte®)” NCT02034682 ↗ “Volulyte® (6% HES 130/0.4 in balanced solution)” NCT07410988 ↗ |
| Known as | Volulyte 6% | “Volulyte 6% (HES 130/0.4 in an isotonic composition)” NCT02034682 ↗ |
| Known as | Voluven | “Goals : Primary endpoint is to demonstrate that colloid (Voluven®) titration, guided using esophageal Doppler estimation of stroke volume, during the surgical repair of hip...” NCT00444262 ↗21“The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES, voluven) administered by gravity at a wide-open rate over a period of 15-30min before...” NCT03107598 ↗ “250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.” NCT02337010 ↗ “In Phase B, 12 subjects will receive 1 litre of PlasmaVolume® (Baxter Health Care, Thetford, UK) or Voluven® (Fresenius Kabi, Bad Homburg, Germany).” NCT01087853 ↗ “hydroxyethyl starch in sodium chloride injection Brand Name: Voluven” NCT05505708 ↗ “Hydroxyethyl starch (Voluven®, fresenius kabi, Germany)” NCT04465539 ↗ “Hydroxyethyl Starch 130/0.4 (Voluven)” NCT00308126 ↗ “Voluven” NCT03249298 ↗ “Voluven” NCT01729364 ↗ |
| Modality | Other / unclassified | “colloid (Voluven®)” NCT00444262 ↗ |
| Route | Intravenous | “intravenous infusion” NCT00300040 ↗ |